Reports of Biochemistry
and Molecular Biology
Mon, Dec 29, 2025
[Archive]
Volume 14, Issue 1 (Vol.14 No.1 Apr 2025)
rbmb.net 2025, 14(1): 124-135 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Alahkhani N, Mohajertehran F, Salehi A, Mohtasham N, Javan- Rashid A, Kamyab hesari K. Gal-3 Expression in Oral and Lip SCC: Histopathological Correlation via Immunohistochemistry. rbmb.net 2025; 14 (1) :124-135
URL: http://rbmb.net/article-1-1627-en.html
URL: http://rbmb.net/article-1-1627-en.html
Negin Alahkhani 
, Farnaz Mohajertehran , Armaghan Salehi , Nooshin Mohtasham , Abdollah Javan- Rashid , Kambiz Kamyab hesari *
, Farnaz Mohajertehran , Armaghan Salehi , Nooshin Mohtasham , Abdollah Javan- Rashid , Kambiz Kamyab hesari *
Department of Dermatopathology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Abstract: (280 Views)
Background: Oral and lip squamous cell carcinomas (OSCC) are malignancies among head and neck cancers. OSCC is characterized by aggressive behavior and poorer prognosis compared to other squamous cell carcinomas. Galectin-3 (Gal-3) is a multifunctional protein involved in processes such as cell proliferation, apoptosis, and metastasis. This study aims to evaluate and compare Gal-3 expression among groups to investigate its role in the biological behaviors of lip and oral SCCs.
Methods: Immunohistochemical analysis of Gal-3 was performed on OSCC and lip SCC samples, with oral and lip marginal tissues obtained as the control group. The clinicopathological parameters, including the invasive front (IF), depth of invasion (DOI), and muscular, neural, and vascular invasions, were assessed. The staining percentage, intensity, and cellular location of Gal-3 were compared between the study groups. A p-value of < 0.05 was considered statistically significant.
Results: Gal-3 staining percentages were significantly higher in the SCC groups compared to control groups (P< 0.001 for each). Staining intensity and nuclear staining were higher in OSCC than in lip SCC (P< 0.001, P< 0.010, respectively). Nuclear Gal-3 was notably associated with the presence of muscle invasion in OSCC (P=0.030). High IF status was correlated with Gal-3 expression in lip SCC (P=0.010). Staining intensity was significantly higher in OSCC samples with vascular invasion compared to those without (P= 0.016).
Conclusion: The higher Gal-3 expression and nuclear staining in OSCC may explain its aggressive nature. Gal-3 could be a diagnostic and prognostic biomarker due to its increased expression in cancerous tissues compared to normal samples.
Keywords: Depth of invasion, Galectin-3, Head and neck squamous cell carcinoma, Invasive front, Immunohistochemistry.
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2025/03/15 | Accepted: 2025/04/26 | Published: 2025/12/9
Received: 2025/03/15 | Accepted: 2025/04/26 | Published: 2025/12/9
References
1. Sharma A, Indu S, Gautami D, Sharma V. Oral squamous cell carcinoma (OSCC) in humans: Etiological Factors, diagnostic and therapeutic relevance. Res J Biotechnol. 2020;15:141-51.
2. Salah M, Rezaee M, Fattahi MJ, Ghaderi A, Khademi B, Mokhtari MJ. Association of lncRNA ANRIL rs10757278 A> G Variant, Tumor Size, Grading, Tumor Site, and Tumor Stage in Oral Squamous Cell Carcinoma Patients. Rep Biochem Mol Biol. 2024;13(1):59-66. [DOI:10.61186/rbmb.13.1.59] [PMID] []
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. [DOI:10.3322/caac.21660] [PMID]
4. Stepan KO, Mazul AL, Larson J, Shah P, Jackson RS, Pipkorn P, et al. Changing Epidemiology of Oral Cavity Cancer in the United States. Otolaryngol Head Neck Surg. 2023 Apr;168(4):761-768. [DOI:10.1177/01945998221098011] [PMID] []
5. Alhabbab R, Johar R. Lip cancer prevalence, epidemiology, diagnosis, and management: A review of the literature. Adv Oral Maxillofacial Surge. 2022;6:100276. [DOI:10.1016/j.adoms.2022.100276]
6. Batista AC, Costa NL, Oton-Leite AF, Mendonça EF, Alencar Rde C, Silva TA. Distinctive clinical and microscopic features of squamous cell carcinoma of oral cavity and lip. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(3):e74-9. [DOI:10.1016/j.tripleo.2009.10.034] [PMID]
7. Chamoli A, Gosavi AS, Shirwadkar UP, Wangdale KV, Behera SK, Kurrey NK, et al. Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics. Oral Oncol. 2021 Oct;121:105451. [DOI:10.1016/j.oraloncology.2021.105451] [PMID]
8. Shahabinejad M, Zare R, Asadi Z, Mohajertehran F. LAMP3 (CD208) Expression in Squamous Cell Carcinoma and Epithelial Dysplasia of the Oral Cavity and Clinicopathological Characteristics of Unfavorable Prognosis. Rep Biochem Mol Biol. 2021;9(4):373-378. [DOI:10.52547/rbmb.9.4.373] []
9. Bota JP, Lyons AB, Carroll BT. Squamous Cell Carcinoma of the Lip-A Review of Squamous Cell Carcinogenesis of the Mucosal and Cutaneous Junction. Dermatol Surg. 2017;43(4):494-506. [DOI:10.1097/DSS.0000000000001020] [PMID]
10. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93-99. [DOI:10.3322/caac.21388] [PMID]
11. Majumdar B, Patil S, Sarode SC, Sarode GS, Rao RS. Clinico-pathological prognosticators in oral squamous cell carcinoma: An update. Transl Res Oral Oncol. 2017;2:2057178X17738912. [DOI:10.1177/2057178X17738912]
12. Sandu K, Nisa L, Monnier P, Simon C, Andrejevic-Blant S, Bron L. Clinicobiological progression and prognosis of oral squamous cell carcinoma in relation to the tumor invasive front: impact on prognosis. Acta Otolaryngol. 2014;134(4):416-24. [DOI:10.3109/00016489.2013.849818] [PMID]
13. Sciacchitano S, Lavra L, Morgante A, Ulivieri A, Magi F, De Francesco GP, et al. Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. Int J Mol Sci. 2018;19(2):379. [DOI:10.3390/ijms19020379] [PMID] []
14. Endo H, Muramatsu T, Furuta M, Uzawa N, Pimkhaokham A, Amagasa T, et al. Potential of tumor-suppressive miR-596 targeting LGALS3BP as a therapeutic agent in oral cancer. Carcinogenesis. 2012;34(3):560-9. [DOI:10.1093/carcin/bgs376] [PMID]
15. Zhang X, Ding H, Lu Z, Ding L, Song Y, Jing Y, et al. Increased LGALS3BP promotes proliferation and migration of oral squamous cell carcinoma via PI3K/AKT pathway. Cell Signal. 2019;63:109359. [DOI:10.1016/j.cellsig.2019.109359] [PMID]
16. Fukamachi M, Kasamatsu A, Endo-Sakamoto Y, Fushimi K, Kasama H, Iyoda M, et al. Multiple coagulation factor deficiency protein 2 as a crucial component in metastasis of human oral cancer. Exp Cell Res. 2018;368(1):119-25. [DOI:10.1016/j.yexcr.2018.04.021] [PMID]
17. Singh P, Verma JK, Singh JK. Validation of Salivary Markers, IL-1β, IL-8 and Lgals3bp for Detection of Oral Squamous Cell Carcinoma in an Indian Population. Sci Rep. 2020;10(1):7365. [DOI:10.1038/s41598-020-64494-3] [PMID] []
18. Kim MJ, Ahn KM. Prognostic factors of oral squamous cell carcinoma: the importance of recurrence and pTNM stage. Maxillofac Plast Reconstr Surg. 2024;46(1):8. [DOI:10.1186/s40902-024-00410-3] [PMID] []
19. González-Moles MÁ, Aguilar-Ruiz M, Ramos-García P. Challenges in the Early Diagnosis of Oral Cancer, Evidence Gaps and Strategies for Improvement: A Scoping Review of Systematic Reviews. Cancers. 2022;14(19):4967. [DOI:10.3390/cancers14194967] [PMID] []
20. Seoane J, Alvarez-Novoa P, Gomez I, Takkouche B, Diz P, Warnakulasiruya S, et al. Early oral cancer diagnosis: The Aarhus statement perspective. A systematic review and meta-analysis. Head Neck. 2016;38(S1):E2182-E9. [DOI:10.1002/hed.24050] [PMID]
21. Rivera C, Oliveira AK, Costa RAP, De Rossi T, Paes Leme AF. Prognostic biomarkers in oral squamous cell carcinoma: A systematic review. Oral Oncol. 2017;72:38-47. [DOI:10.1016/j.oraloncology.2017.07.003] [PMID]
22. Wang Y, Liu S, Tian Y, Wang Y, Zhang Q, Zhou X, et al. Prognostic role of galectin-3 expression in patients with solid tumors: a meta-analysis of 36 eligible studies. Cancer Cell Int. 2018;18:172. [DOI:10.1186/s12935-018-0668-y] [PMID] []
23. Coppock JD, Mills AM, Stelow EB. Galectin-3 Expression in High-Risk HPV-Positive and Negative Head & Neck Squamous Cell Carcinomas and Regional Lymph Node Metastases. Head Neck Pathol. 2021;15(1):163-8. [DOI:10.1007/s12105-020-01195-3] [PMID] []
24. Delorge S, Saussez S, Pelc P, Devroede B, Marchant H, Burchert M, et al. Correlation of galectin-3/galectin-3-binding sites with low differentiation status in head and neck squamous cell carcinomas. Otolaryngol Head Neck Surg. 2000;122(6):834-41.
https://doi.org/10.1016/S0194-5998(00)70010-6 [DOI:10.1016/S0194-59980070010-6] [PMID]
25. Braeuer RR, Zigler M, Kamiya T, Dobroff AS, Huang L, Choi W, et al. Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res. 2012;72(22):5757-66. [DOI:10.1158/0008-5472.CAN-12-2424] [PMID] []
26. Aggarwal S, Sharma SC, Das SN. Galectin-1 and galectin-3: Plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population. Clin Chim Acta. 2015;442:13-21. [DOI:10.1016/j.cca.2014.12.038] [PMID]
27. Scafetta G, D'Alessandria C, Bartolazzi A. Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape. Journal of Experimental & Clinical Cancer Research. 2024;43(1):41. [DOI:10.1186/s13046-024-02968-2] [PMID] []
28. Bota JP, Lyons AB, Carroll BT. Squamous Cell Carcinoma of the Lip-A Review of Squamous Cell Carcinogenesis of the Mucosal and Cutaneous Junction. Dermatol Surg. 2017;43(4):494-506. [DOI:10.1097/DSS.0000000000001020] [PMID]
29. Wang LP, Chen SW, Zhuang SM, Li H, Song M. Galectin-3 accelerates the progression of oral tongue squamous cell carcinoma via a Wnt/β-catenin-dependent pathway. Pathol Oncol Res. 2013;19(3):461-74. [DOI:10.1007/s12253-013-9603-7] [PMID]
30. Saussez S, Lorfevre F, Lequeux T, Laurent G, Chantrain G, Vertongen F, et al. The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol. 2008;44(1):86-93. [DOI:10.1016/j.oraloncology.2006.12.014] [PMID]
31. Selvaraj FM, Joseph AP, Varun BR, Mony V, Siva Kumar TT. Immunohistochemical Evaluation of Galectin-3 Expression in Oral Squamous Cell Carcinoma, Oral Leukoplakia and Normal Mucosa. Indian J Dent Res. 2022;33(3):282-6. [DOI:10.4103/ijdr.ijdr_157_22] [PMID]
32. Al-Maghrabi JA, Khabaz MN. Clinical significance of galectin-3 expression in urinary bladder carcinoma. J Int Med Res. 2023;51(2):3000605231153323. [DOI:10.1177/03000605231153323] [PMID] []
33. Tokmak S, Arık D, Pınarbaşlı Ö, Gürbüz MK, Açıkalın MF. Evaluation and Prognostic Significance of Galectin-3 Expression in Oral Squamous Cell Carcinoma. Ear Nose Throat J. 2019;100(5 Suppl):578S-83S. [DOI:10.1177/0145561319893861] [PMID]
34. Weber M, Büttner-Herold M, Distel L, Ries J, Moebius P, Preidl R, et al. Galectin 3 expression in primary oral squamous cell carcinomas. BMC Cancer. 2017;17(1):906. [DOI:10.1186/s12885-017-3920-2] [PMID] []
35. Nakahara S, Raz A. Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. Cancer Metastasis Rev. 2007;26(3-4):605-10. [DOI:10.1007/s10555-007-9095-6] [PMID] []
36. Lin HM, Pestell RG, Raz A, Kim HR. Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene. 2002;21(52):8001-10. [DOI:10.1038/sj.onc.1205820] [PMID]
37. Paron I, Scaloni A, Pines A, Bachi A, Liu FT, Puppin C, et al. Nuclear localization of Galectin-3 in transformed thyroid cells: a role in transcriptional regulation. Biochem Biophys Res Commun. 2003;302(3):545-53. [DOI:10.1016/S0006-291X(03)00151-7] [PMID]
38. Pătru A, Şurlin V, Mărgăritescu C, Ciucă EM, Matei M, Dumitrescu D, et al. Immunohistochemical evaluation of D2-40, Galectin-3, Maspin and MCM7 expression in palate squamous cell carcinomas. Rom J Morphol Embryol. 2021;62(1):133-49. [DOI:10.47162/RJME.62.1.13] [PMID] []
39. Alves PM, Godoy GP, Gomes DQ, Medeiros AMC, de Souza LB, da Silveira EJD, et al. Significance of galectins-1, -3, -4 and -7 in the progression of squamous cell carcinoma of the tongue. Pathol Res Pract. 2011;207(4):236-40. [DOI:10.1016/j.prp.2011.02.004] [PMID]
40. Cela I, Caponio VCA, Capone E, Pinti M, Mascitti M, Togni L, et al. LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma. Oral Dis. 2024;30(4):2039-50. [DOI:10.1111/odi.14719] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
